Scapa Healthcare continues to make significant investments to meet growing customer demands for medical-grade hydrocolloid adhesive technologies globally. For instance, enhancements at its Hydrocolloid Technology Center in Orangeburg, NY, include new automated and visual systems for ostomy and consumer products as well as enhancements to high-speed finished packaging, R&D capabilities, unique device identifier (UDI) systems for medical devices, and forecasting and supply chain management tools, the company reported in a news release.

Featuring a Class 8 cleanroom environment, the site is ISO 13485 and cGMP certified, FDA registered for medical device manufacturing, and holds a Japanese Certification as a Foreign Medical Device Manufacturer (J-PAL Japan PMDA).

“We are thrilled to announce another significant investment at one of our key technology centers,” said John Petreanu, president of Scapa Healthcare, in a news release. “Hydrocolloid technology has been experiencing tremendous growth as new and innovative applications are uncovered for skin care and medical device markets. We look forward to continue supporting our customers with this technology, offering the expertise and capabilities needed to provide optimal solutions leveraging our 30 plus years of experience in hydrocolloid development.”

The Scapa Healthcare Hydrocolloid Technology Center specializes in designing, developing, and manufacturing proprietary hydrocolloid formulations for skin friendly fixation applications including advanced wound dressings, negative pressure wound therapy drapes, first aid and foot care consumer bandages, face and beauty aids, ostomy accessories, and custom wearable medical fixation and diagnostic devices, the company reported. It also offers market-ready products for private label as well as custom solutions based on customer needs.